Cargando…
Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma
Kaposi’s sarcoma-associated herpesvirus (KSHV) causes primary effusion lymphoma (PEL). The cellular transcription factor (TF) interferon (IFN) regulatory factor 4 (IRF4) is an essential oncogene in PEL, but its specific role in PEL and how KSHV deregulates IRF4 remain unknown. Here, we report that t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448273/ https://www.ncbi.nlm.nih.gov/pubmed/32843547 http://dx.doi.org/10.1128/mBio.01457-20 |
_version_ | 1783574469237800960 |
---|---|
author | Manzano, Mark Günther, Thomas Ju, Hyunwoo Nicholas, John Bartom, Elizabeth T. Grundhoff, Adam Gottwein, Eva |
author_facet | Manzano, Mark Günther, Thomas Ju, Hyunwoo Nicholas, John Bartom, Elizabeth T. Grundhoff, Adam Gottwein, Eva |
author_sort | Manzano, Mark |
collection | PubMed |
description | Kaposi’s sarcoma-associated herpesvirus (KSHV) causes primary effusion lymphoma (PEL). The cellular transcription factor (TF) interferon (IFN) regulatory factor 4 (IRF4) is an essential oncogene in PEL, but its specific role in PEL and how KSHV deregulates IRF4 remain unknown. Here, we report that the KSHV latency protein viral interferon regulatory factor 3 (vIRF3) cooperates with IRF4 and cellular BATF (basic leucine zipper ATF-like TF) to drive a super-enhancer (SE)-mediated oncogenic transcriptional program in PEL. Chromatin immunoprecipitation coupled with next-generation sequencing (ChIP-Seq) experiments demonstrated that IRF4, vIRF3, and BATF cooccupy the SEs of key survival genes, in a pattern that is distinct from those seen with other IRF4-driven malignancies. All three proteins cooperatively drive SE-mediated IRF4 overexpression. Inactivation of vIRF3 and, to a lesser extent, BATF phenocopies the gene expression changes and loss of cellular viability observed upon inactivation of IRF4. In sum, this work suggests that KSHV vIRF3 and cellular IRF4 and BATF cooperate as oncogenic transcription factors on SEs to promote cellular survival and proliferation in KSHV-associated lymphomas. |
format | Online Article Text |
id | pubmed-7448273 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-74482732020-09-02 Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma Manzano, Mark Günther, Thomas Ju, Hyunwoo Nicholas, John Bartom, Elizabeth T. Grundhoff, Adam Gottwein, Eva mBio Research Article Kaposi’s sarcoma-associated herpesvirus (KSHV) causes primary effusion lymphoma (PEL). The cellular transcription factor (TF) interferon (IFN) regulatory factor 4 (IRF4) is an essential oncogene in PEL, but its specific role in PEL and how KSHV deregulates IRF4 remain unknown. Here, we report that the KSHV latency protein viral interferon regulatory factor 3 (vIRF3) cooperates with IRF4 and cellular BATF (basic leucine zipper ATF-like TF) to drive a super-enhancer (SE)-mediated oncogenic transcriptional program in PEL. Chromatin immunoprecipitation coupled with next-generation sequencing (ChIP-Seq) experiments demonstrated that IRF4, vIRF3, and BATF cooccupy the SEs of key survival genes, in a pattern that is distinct from those seen with other IRF4-driven malignancies. All three proteins cooperatively drive SE-mediated IRF4 overexpression. Inactivation of vIRF3 and, to a lesser extent, BATF phenocopies the gene expression changes and loss of cellular viability observed upon inactivation of IRF4. In sum, this work suggests that KSHV vIRF3 and cellular IRF4 and BATF cooperate as oncogenic transcription factors on SEs to promote cellular survival and proliferation in KSHV-associated lymphomas. American Society for Microbiology 2020-08-25 /pmc/articles/PMC7448273/ /pubmed/32843547 http://dx.doi.org/10.1128/mBio.01457-20 Text en Copyright © 2020 Manzano et al. https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Article Manzano, Mark Günther, Thomas Ju, Hyunwoo Nicholas, John Bartom, Elizabeth T. Grundhoff, Adam Gottwein, Eva Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma |
title | Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma |
title_full | Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma |
title_fullStr | Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma |
title_full_unstemmed | Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma |
title_short | Kaposi’s Sarcoma-Associated Herpesvirus Drives a Super-Enhancer-Mediated Survival Gene Expression Program in Primary Effusion Lymphoma |
title_sort | kaposi’s sarcoma-associated herpesvirus drives a super-enhancer-mediated survival gene expression program in primary effusion lymphoma |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448273/ https://www.ncbi.nlm.nih.gov/pubmed/32843547 http://dx.doi.org/10.1128/mBio.01457-20 |
work_keys_str_mv | AT manzanomark kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma AT guntherthomas kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma AT juhyunwoo kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma AT nicholasjohn kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma AT bartomelizabetht kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma AT grundhoffadam kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma AT gottweineva kaposissarcomaassociatedherpesvirusdrivesasuperenhancermediatedsurvivalgeneexpressionprograminprimaryeffusionlymphoma |